Clearside Biomedical Announces Six ARVO 2025 Abstracts
Clearside Biomedical announced the acceptance of six abstracts for presentation at the 2025 ARVO meeting. These abstracts cover topics...
Tonix Pharmaceuticals Advances NDA: TNX-102 SL for Fibromyalgia
Tonix Pharmaceuticals announced that the FDA will not require an advisory committee meeting for their New Drug Application (NDA)...
Phentolamine Solution for Dim Light Disturbances at WCC IX
Opus Genetics announced positive Phase 3 results for its Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances,...
Clearmind’s Psychedelic CMND-100 Arrives in US for Yale Trial
Clearmind Medicine Inc. (Nasdaq: CMND) has shipped its novel psychedelic-derived drug candidate, CMND-100, to the United States for its...
Silexion Unveils Sil204 Plan at NEAUXCancer 2025
Silexion Therapeutics has developed an expanded plan for SIL204, its next-generation siRNA candidate targeting KRAS-driven cancers. The company will...
Opthea Coast Phase 3 Trial Fails to Meet Primary Endpoint
Opthea Limited’s Phase 3 COAST trial for sozinibercept, a combination therapy with aflibercept for wet age-related macular degeneration (wet...
Nanobiotix Data from Two Phase 1 NBTXR3 Studies at ELC
Nanobiotix announced two poster presentations at the 2025 European Lung Cancer Conference showcasing Phase 1 study data for JNJ-1900...
CEPI Funds Dyadic’s C1 for Protein Vaccine Development
Dyadic International received a $4.5 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to explore using their...
Briacell’s Phase 3 Breast Cancer Study Gets Positive Recommendation
BriaCell Therapeutics Corp. announced positive safety results from the second review of its Phase 3 study of Bria-IMT™ combined...
Medera Gets DSMB Clearance to Advance Phase 2 Portion of Phase 1b/2 Trial for Gene Therapy in Heart Failure
Medera Inc., a clinical-stage biopharmaceutical company, announced positive results from the Phase 1b portion of its MUSIC-HFrEF trial, evaluating...